BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

67.36 -0.19 (-0.29%)

Streaming Delayed Price Updated: 12:45 PM EDT, Jun 12, 2026 Add to My Watchlist

Price and Volume

Volume	504,730
Open	67.67
Bid (Size)	67.28 (100)
Ask (Size)	67.45 (100)
Prev. Close	67.55
Today's Range	66.86 - 68.20
52wk Range	38.57 - 84.94
Shares Outstanding	160,500,999
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

May 27, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches ↗

May 13, 2026

BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three...

Via MarketBeat

Performance

YTD	-13.9%	-13.9%
1 Month	+2.1%	+2.1%
3 Month	-0.9%	-0.9%
6 Month	-9.1%	-9.1%
1 Year	+72.5%	+72.5%

More News

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

May 12, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

May 11, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma (NASDAQ:BBIO) Q1 2026 Revenue Beat Driven by Attruby Sales Surge, Shares Jump ↗

May 07, 2026

Via Chartmill

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 08, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio (BBIO) Q1 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

May 07, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Participate in May and June Investor Conferences

May 06, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

May 06, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE

May 05, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

May 04, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

April 30, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio (BBIO) Q2 2025 Earnings Transcript ↗

April 28, 2026

Via The Motley Fool

BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White

April 28, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 22, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity

April 13, 2026

Via MarketMinute

BridgeBio Pharma Inc (NASDAQ:BBIO) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗

April 11, 2026

Via Chartmill

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

March 30, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

March 30, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

March 23, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

March 20, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

March 11, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

March 04, 2026

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio (BBIO) Q4 2025 Earnings Call Transcript ↗

February 24, 2026

Via The Motley Fool

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?

Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.

What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?

BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?

The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market

What is the current price of BridgeBio Pharma, Inc. - Common Stock?

The current price of BridgeBio Pharma, Inc. - Common Stock is 67.36

When was BridgeBio Pharma, Inc. - Common Stock last traded?

The last trade of BridgeBio Pharma, Inc. - Common Stock was at 06/12/26 12:45 PM ET

What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?

The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 10.81B

How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?

BridgeBio Pharma, Inc. - Common Stock has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.